(NASDAQ)
40.79
+1.00   (+4.26%)
 
Volume (24h) Market Cap. Day Range 52w Range
2,493 1.18B 40.05 - 40.78 26.66 - 73.84
Jan-26-21 08:00AM Cortexyme Announces Pipeline Update and Anticipated 2021 MilestonesBusiness Wire
Jan-06-21 08:49AM Is the Options Market Predicting a Spike in Cortexyme (CRTX) Stock?Zacks
Dec-07-20 12:49PM Is Cortexyme (CRTX) A Good Stock To Buy Now?Insider Monkey
Dec-04-20 07:43AM The Daily Biotech Pulse: BioCryst's Heredity Angioedema Treatment Clears FDA, Sutro Biopharma Readout, 2 IPOsBenzinga
07:00AM Cortexyme’s Phase 2/3 GAIN Trial of Atuzaginstat (COR388) in Patients with Alzheimer’s Disease Successfully Advances Past Interim AnalysisBusiness Wire
Dec-01-20 08:40AM Is the Options Market Predicting a Spike in Cortexyme (CRTX) Stock?Zacks
Nov-27-20 10:27AM New Strong Sell Stocks for November 27thZacks
Nov-20-20 10:45AM New Strong Sell Stocks for November 20thZacks
Nov-12-20 04:30AM Cortexyme Announces Third Quarter 2020 Financial Results and Provides Business UpdateBusiness Wire
Nov-10-20 07:12AM Are Insiders Buying Cortexyme, Inc. (NASDAQ:CRTX) Stock?Simply Wall St.
Nov-05-20 08:00AM Cortexyme Presents an Update and Baseline Data from the Phase 2/3 GAIN Trial of Atuzaginstat at CTAD 2020, the Clinical Trials on Alzheimer’s Disease ConferenceBusiness Wire
Oct-19-20 08:00AM Cortexyme Announces Upcoming Data Presentations at November 2020 ConferencesBusiness Wire
Sep-24-20 08:00AM Cortexyme Announces GAIN Trial of Atuzaginstat in Alzheimer’s Disease Has Exceeded Study Enrollment Target of 570 PatientsBusiness Wire
Sep-09-20 08:00AM Cortexyme to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020Business Wire
Aug-27-20 08:00AM Cortexyme Announces Issuance of Composition of Matter Patent for Atuzaginstat by the U.S. Patent and Trademark OfficeBusiness Wire
Aug-18-20 09:21AM Company News for Aug 18, 2020Zacks
Aug-17-20 08:00AM Cortexyme Announces Second Quarter 2020 Financial Results and Provides Business UpdateBusiness Wire
Aug-14-20 08:00AM Cortexyme Announces GAIN Trial of Atuzaginstat in Alzheimer’s Disease Has Reached Enrollment Milestone of 500 PatientsBusiness Wire
Aug-12-20 08:11AM We're Hopeful That Cortexyme (NASDAQ:CRTX) Will Use Its Cash WiselySimply Wall St.
08:10AM Here's Why We're Not Too Worried About Cortexyme's (NASDAQ:CRTX) Cash Burn SituationSimply Wall St.
Aug-06-20 04:05AM Cortexyme Announces Webcasts of Investor Conference Presentations in August 2020Business Wire
Jul-29-20 08:00AM Cortexyme to Participate in Virtual Fireside Chat Hosted by LifeSci Capital on July 30, 2020Business Wire
Jul-28-20 06:09AM Cortexyme Presents Data Linking P. gingivalis Infection to Cardiovascular Disease Severity and Alzheimer's Disease, Along With Evidence That Treatment With Atuzaginstat (COR388) Improves Biomarkers Associated With Both DiseasesBusiness Wire
Jul-22-20 08:00AM Cortexyme Announces Upcoming Data Presentations at the Alzheimer’s Association International Conference 2020Business Wire
Jun-12-20 04:27AM Hedge Funds Are Buying Cortexyme, Inc. (CRTX)Insider Monkey
Jun-09-20 08:00AM Cortexyme Announces "Atuzaginstat" Selected as First-in-Class Nonproprietary Name for COR388Business Wire
Jun-02-20 09:44AM Benzinga's Top Upgrades, Downgrades For June 2, 2020Benzinga
May-27-20 08:00AM Cortexyme to Present at the Jefferies Virtual Healthcare Conference on June 2, 2020Business Wire
May-14-20 11:44AM Are Insiders Buying Cortexyme, Inc. (NASDAQ:CRTX) Stock?Simply Wall St.
May-12-20 04:05AM Cortexyme Announces First Quarter 2020 Financial Results and Provides Business UpdateBusiness Wire
May-07-20 08:00AM Cortexyme to Present at the BofA Securities 2020 Health Care Conference on May 13, 2020Business Wire
May-06-20 08:30AM Cortexyme Publishes Data on P. Gingivalis Ability to Infect Neurons, Drive Alzheimer’s-Like Pathology in the Journal of Alzheimer’s DiseaseBusiness Wire
Apr-30-20 04:05AM Cortexyme Appoints Caryn McDowell, J.D. as Chief Legal and Administrative Officer and Corporate SecretaryBusiness Wire
Apr-06-20 08:30AM Cortexyme to Present at the LifeSci Capital Alpha Series Virtual Conference on April 9, 2020Business Wire
Apr-02-20 08:00AM Cortexyme Presents Data Supporting Role of P. Gingivalis in Alzheimer’s Pathology at Advances in Alzheimer’s and Parkinson’s Therapies Virtual Focus Meeting 2020Business Wire
Mar-17-20 08:00AM Cortexyme Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Business UpdateBusiness Wire
Mar-16-20 08:00AM Cortexyme Announces Gain Trial in Alzheimer’s Disease Has Reached Enrollment Milestone of 300 PatientsBusiness Wire
Feb-13-20 08:00AM Cortexyme Provides Regulatory Update for COR388 Development Program in Alzheimer’s DiseaseBusiness Wire
Feb-10-20 04:05AM Cortexyme Announces Closing of $125 Million Private PlacementBusiness Wire
Feb-05-20 09:00AM Cortexyme Announces $125 Million Private PlacementBusiness Wire
Jan-30-20 08:18AM Cortexyme Announces Publication of New Data Further Demonstrating the Therapeutic Potential of COR388, the Company’s Lead Investigational MedicineBusiness Wire
Jan-13-20 08:00AM Cortexyme Announces the Initiation of an Open-Label Extension Study for the GAIN Trial of COR388 in Alzheimer’s DiseaseBusiness Wire
Jan-08-20 04:05AM Cortexyme to Present at the 3rd Annual Neuroscience Innovation Forum on January 12, 2020Business Wire
Jan-03-20 10:15AM Last year's Bay Area IPO performances show why it pays to be an insiderAmerican City Business Journals
Dec-22-19 06:38AM Hedge Funds Have Never Been This Bullish On Cortexyme, Inc. (CRTX)Insider Monkey
Dec-13-19 11:16AM The Zacks Analyst Blog Highlights: Alibaba, Beyond Meat, Cortexyme, Revolve and UberZacks
Dec-11-19 06:32AM 5 Hottest IPOs of 2019Zacks
Dec-09-19 08:44AM Fiverr Languishes Below IPO Price as First Chance to Sell NearsBloomberg
Dec-07-19 01:00AM Cortexyme Announces Presentation of Data Revealing Link Between Bacterial Pathogen and Genetic Risk for Alzheimer’s DiseaseBusiness Wire
Nov-26-19 04:05AM Cortexyme to Present at the Evercore ISI 2nd Annual HealthCONx Conference on December 3, 2019Business Wire
Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders. Its lead drug candidate is COR388, an orally-administered brain-penetrating small molecule gingipain inhibitor, which has completed Phase 1a and Phase 1b clinical trials for use in patients with mild to moderate Alzheimer's disease. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Cap:    |  Volume (24h):